David A.  Ricks net worth and biography

David Ricks Biography and Net Worth

Dave Ricks is chair and chief executive officer of Eli Lilly and Company. A Lilly veteran for more than 25 years, with experience in marketing, sales, drug development and international operations, Dave became CEO in January 2017 and was elected chair of the company’s board of directors effective June 2017. 

Dave served as president of Lilly Bio-Medicines from 2012 through 2016. He led the company’s largest affiliate, Lilly USA, as president from 2009 to 2012.

Prior to that, Dave served in international leadership roles for nearly eight years. He served as president and general manager of Lilly China, operating in one of the world’s fastest-growing emerging markets, from 2008 to 2009. He led Lilly Canada as general manager from 2005 to 2008, after roles as director of pharmaceutical marketing and national sales director in that country. Dave joined Lilly in 1996 as a business development associate and held several management roles in U.S. marketing and sales before moving to Lilly Canada.

Dave earned a Bachelor of Science degree from Purdue University in 1990 and a Master of Business Administration degree from Indiana University in 1996. 

Dave is on the board of Adobe and is the immediate past chair of the board of the Pharmaceutical Research and Manufacturers of America (PhRMA). Dave is a member of the International Federation of Pharmaceutical Manufacturers & Association's CEO Steering Committee, The Business Council, Business Roundtable, and the U.S. Patent and Trademark Office’s Council for Inclusive Innovation. 

Closer to home, Dave is also heavily engaged in the development and well-being of Central Indiana. He serves on the board of the Central Indiana Corporate Partnership and on the Riley Children’s Foundation board of governors.

What is David A. Ricks' net worth?

The estimated net worth of David A. Ricks is at least $3.77 million as of September 27th, 2022. Mr. Ricks owns 5,139 shares of Eli Lilly and Company stock worth more than $3,769,508 as of April 26th. This net worth approximation does not reflect any other investments that Mr. Ricks may own. Additionally, Mr. Ricks receives a salary of $6,290,000.00 as CEO at Eli Lilly and Company. Learn More about David A. Ricks' net worth.

How old is David A. Ricks?

Mr. Ricks is currently 56 years old. There are 7 older executives and no younger executives at Eli Lilly and Company. Learn More on David A. Ricks' age.

What is David A. Ricks' salary?

As the CEO of Eli Lilly and Company, Mr. Ricks earns $6,290,000.00 per year. Learn More on David A. Ricks' salary.

How do I contact David A. Ricks?

The corporate mailing address for Mr. Ricks and other Eli Lilly and Company executives is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. Eli Lilly and Company can also be reached via phone at (317) 276-2000 and via email at [email protected]. Learn More on David A. Ricks' contact information.

Has David A. Ricks been buying or selling shares of Eli Lilly and Company?

David A. Ricks has not been actively trading shares of Eli Lilly and Company during the last quarter. Most recently, on Friday, October 25th, David A. Ricks bought 4,615 shares of Eli Lilly and Company stock. The stock was acquired at an average cost of $108.38 per share, with a total value of $500,173.70. Following the completion of the transaction, the chief executive officer now directly owns 157,405 shares of the company's stock, valued at $17,059,553.90. Learn More on David A. Ricks' trading history.

Who are Eli Lilly and Company's active insiders?

Eli Lilly and Company's insider roster includes Anat Ashkenazi (Sr. VP & CFO ), Melissa Barnes (SVP), Enrique Conterno (SVP), Stephen Fry (SVP), Michael Harrington (VP), Susan Mahony (SVP), Johna Norton (EVP), Myles O'Neill (SVP), Derica Rice (EVP), David Ricks (CEO), Marschall Runge (Director), Aarti Shah (SVP), Christi Shaw (SVP), Jeffrey Simmons (SVP), Daniel Skovronsky (SVP), Joshua Smiley (CFO), Jackson Tai (Director), Jacob Van Naarden (Sr. VP), Alonzo Weems (SVP), Anne White (SVP), Ilya Yuffa (SVP), Donald Zakrowski (CAO), and Alfonso Zulueta (SVP). Learn More on Eli Lilly and Company's active insiders.

Are insiders buying or selling shares of Eli Lilly and Company?

In the last year, insiders at the sold shares 31 times. They sold a total of 2,074,936 shares worth more than $21,628,352,978.48. The most recent insider tranaction occured on January, 31st when Major Shareholder Lilly Endowment Inc sold 78,573 shares worth more than $50,920,804.11. Insiders at Eli Lilly and Company own 0.1% of the company. Learn More about insider trades at Eli Lilly and Company.

Information on this page was last updated on 1/31/2024.

David A. Ricks Insider Trading History at Eli Lilly and Company

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/25/2019Buy4,615$108.38$500,173.70157,405View SEC Filing Icon  
2/3/2016Sell5,733$77.66$445,224.7879,403View SEC Filing Icon  
2/4/2015Sell3,147$69.99$220,258.53View SEC Filing Icon  
2/2/2015Sell4,769$71.51$341,031.19View SEC Filing Icon  
See Full Table

David A. Ricks Buying and Selling Activity at Eli Lilly and Company

This chart shows David A Ricks's buying and selling at Eli Lilly and Company by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Eli Lilly and Company Company Overview

Eli Lilly and Company logo
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Read More

Today's Range

Now: $733.51
Low: $721.00
High: $737.45

50 Day Range

MA: $761.79
Low: $724.87
High: $792.28

2 Week Range

Now: $733.51
Low: $380.77
High: $800.78

Volume

1,998,801 shs

Average Volume

3,021,320 shs

Market Capitalization

$696.95 billion

P/E Ratio

126.47

Dividend Yield

0.71%

Beta

0.34